Effect of Vibration and Non-Vibration Foam Rolling

March 12, 2026 updated by: Erhan Seçer, Celal Bayar University

Immediate Effects of Vibration and Non-vibration Foam Rolling on the Biomechanical and Viscoelastic Properties of Knee Flexor and Extensor Muscles in Young Male Recreational Athletes: a Randomized, Controlled, Cross-over Study

This study aims to compare the immediate effects of vibration and non-vibration foam rolling on the biomechanical and viscoelastic properties of knee flexor and extensor muscles in young male recreational athletes. Fourteen athletes will be included in this study, planned as a randomized controlled cross-over study. All athletes will complete three interventions: 1) vibration foam rolling (VFR), 2) non-vibration foam rolling (FR), and 3) rest control. Pre- and post-test assessment will include the biomechanical and viscoelastic properties of knee flexor and extensor muscles, assessed with the MyotonPro.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
14

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • To volunteer to participate in the study
  • To engage in sports activities at least 2-3 days a week

Exclusion Criteria:

  • Players with a history of major sports injury or time-loss injury that required surgery
  • Musculoskeletal problems that compromised their performance in the study
  • A history of lower extremity pathology in the 3 months before the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
No Intervention: Control Group
No intervention will be applied to the control group.
Active Comparator: VFR Group
Athletes will be performed three sets of VFR for 30 s, with a 30 s break between each set and exercise. The rolling frequency will be standardized using a metronome set at 60 beats per minute. Athletes will be instructed to roll at a velocity of two metronome beats for each rolling direction. Intensity of pressure will be controlled with a target rating of 7 of 10 on a Numerical Rating Scale (0 = no discomfort and 10 = maximum discomfort) during VFR intervention. The target muscle groups will be the anterior and posterior thigh. During VFR, the vibrator booster will be set to a frequency of 48 hz, which is within the optimal frequency range (12 to 90 hz) to influence the musculoskeletal system, and an amplitude of 1.95 mm.
Other: VFR
Athletes will be performed three sets of VFR for 30 s, with a 30 s break between each set and exercise. The rolling frequency will be standardized using a metronome set at 60 beats per minute. Athletes will be instructed to roll at a velocity of two metronome beats for each rolling direction. Intensity of pressure will be controlled with a target rating of 7 of 10 on a Numerical Rating Scale (0 = no discomfort and 10 = maximum discomfort) during VFR intervention. The target muscle groups will be the anterior and posterior thigh. During VFR, the vibrator booster will be set to a frequency of 48 hz, which is within the optimal frequency range (12 to 90 hz) to influence the musculoskeletal system, and an amplitude of 1.95 mm.
Active Comparator: FR Group
Athletes will be performed three sets of FR for 30 s, with a 30 s break between each set and exercise. The rolling frequency will be standardized using a metronome set at 60 beats per minute. Athletes will be instructed to roll at a velocity of two metronome beats for each rolling direction. Intensity of pressure will be controlled with a target rating of 7 of 10 on a Numerical Rating Scale (0 = no discomfort and 10 = maximum discomfort) during FR intervention. The target muscle groups will be the anterior and posterior thigh. The FR will be conducted using the same vibration foam rolling device, but with the vibration mode deactivated. This ensures that the physical dimensions and material properties of the roller remain constant across conditions, with the only variable being the presence or absence of mechanical vibration.
Other: FR
Athletes will be performed three sets of FR for 30 s, with a 30 s break between each set and exercise. The rolling frequency will be standardized using a metronome set at 60 beats per minute. Athletes will be instructed to roll at a velocity of two metronome beats for each rolling direction. Intensity of pressure will be controlled with a target rating of 7 of 10 on a Numerical Rating Scale (0 = no discomfort and 10 = maximum discomfort) during FR intervention. The target muscle groups will be the anterior and posterior thigh. The FR will be conducted using the same vibration foam rolling device, but with the vibration mode deactivated. This ensures that the physical dimensions and material properties of the roller remain constant across conditions, with the only variable being the presence or absence of mechanical vibration.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Muscle tone
Time Frame: one week
The muscle tone (Hz), as a biomechanical property of the knee flexors and extensors, will be assessed using the MyotonPro (Myoton AS, Tallinn, Estonia). The rectus femoris will be preferred as the primary extensor and the biceps femoris as the principal flexor for the assessment, due to their anatomical and functional centrality. To ensure accuracy, the probe will be applied perpendicularly in three successive increments, with automatic alerts for any deviation. The rectus femoris measurement will be taken at the midpoint between the anterior superior iliac spine and the medial patellar border, with the subject supine and a 20 cm roller under the knees. For the biceps femoris, the subject will be prone with an ankle pillow for relaxation, with measurements taken at the midpoint of the long head's longitudinal axis to ensure consistency. Each muscle will be measured twice in immediate succession, using the mean for analysis.
one week
Stiffness
Time Frame: one week
The stiffness (N/m), as a biomechanical property of the knee flexors and extensors, will be assessed using the MyotonPro (Myoton AS, Tallinn, Estonia). The rectus femoris will be preferred as the primary extensor and the biceps femoris as the principal flexor for the assessment, due to their anatomical and functional centrality. To ensure accuracy, the probe will be applied perpendicularly in three successive increments, with automatic alerts for any deviation. The rectus femoris measurement will be taken at the midpoint between the anterior superior iliac spine and the medial patellar border, with the subject supine and a 20 cm roller under the knees. For the biceps femoris, the subject will be prone with an ankle pillow for relaxation, with measurements taken at the midpoint of the long head's longitudinal axis to ensure consistency. Each muscle will be measured twice in immediate succession, using the mean for analysis.
one week
Elasticity
Time Frame: one week
The elasticity (unitless), as a biomechanical property of the knee flexors and extensors, will be assessed using the MyotonPro (Myoton AS, Tallinn, Estonia). The rectus femoris will be preferred as the primary extensor and the biceps femoris as the principal flexor for the assessment, due to their anatomical and functional centrality. To ensure accuracy, the probe will be applied perpendicularly in three successive increments, with automatic alerts for any deviation. The rectus femoris measurement will be taken at the midpoint between the anterior superior iliac spine and the medial patellar border, with the subject supine and a 20 cm roller under the knees. For the biceps femoris, the subject will be prone with an ankle pillow for relaxation, with measurements taken at the midpoint of the long head's longitudinal axis to ensure consistency. Each muscle will be measured twice in immediate succession, using the mean for analysis.
one week

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
The mechanical stress relaxation time
Time Frame: one week
The mechanical stress relaxation time (ms), as a viscoelastic property of the knee flexors and extensors, will be assessed using the MyotonPro (Myoton AS, Tallinn, Estonia). The rectus femoris will be preferred as the primary extensor and the biceps femoris as the principal flexor for the assessment, due to their anatomical and functional centrality. To ensure accuracy, the probe will be applied perpendicularly in three successive increments, with automatic alerts for any deviation. The rectus femoris measurement will be taken at the midpoint between the anterior superior iliac spine and the medial patellar border, with the subject supine and a 20 cm roller under the knees. For the biceps femoris, the subject will be prone with an ankle pillow for relaxation, with measurements taken at the midpoint of the long head's longitudinal axis to ensure consistency. Each muscle will be measured twice in immediate succession, using the mean for analysis.
one week
The ratio of relaxation and deformation time
Time Frame: one week
The ratio of deformation and relaxation time (unitless), as a viscoelastic property of the knee flexors and extensors, will be assessed using the MyotonPro (Myoton AS, Tallinn, Estonia). The rectus femoris will be preferred as the primary extensor and the biceps femoris as the principal flexor for the assessment, due to their anatomical and functional centrality. To ensure accuracy, the probe will be applied perpendicularly in three successive increments, with automatic alerts for any deviation. The rectus femoris measurement will be taken at the midpoint between the anterior superior iliac spine and the medial patellar border, with the subject supine and a 20 cm roller under the knees. For the biceps femoris, the subject will be prone with an ankle pillow for relaxation, with measurements taken at the midpoint of the long head's longitudinal axis to ensure consistency. Each muscle will be measured twice in immediate succession, using the mean for analysis.
one week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Celal Bayar University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 10, 2026

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 25, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 25, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 4, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 10, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 17, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 13, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 12, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CBU-FTR-ES-O8

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings